 WTHI [1] |
Amylin Seeks FDA Approval on Extended Byetta Treatment [2]
Wall Street Journal By DAVID BENOIT NEW YORK — Amylin Pharmaceuticals Inc. has submitted a new drug application to the Food and Drug Administration for the once-a-week version of its diabetes treatment [3] Byetta, a potential blockbuster drug for the biopharmaceutical … Calif. Drug Maker Seeks Approval for Once-a-Week Diabetes Treatment [4] Attorney at Law Exenatide Once Weekly New Drug Application Submitted to FDA for … [2] PR Newswire (press release) Amylin Shares Jump on NDA but Drug Class Concerns Linger [5] BioWorld Online Trading Markets (press release) [6] – MarketWatch [7] all 205 news articles [8] |
More details can be found at www.diabeteshowto.com [9]